Endometrial Cancer Trial, Recruiting NCT04403867 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04403867
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with early-stage uterine (endometrial) cancer and are scheduled to have a procedure to check nearby lymph nodes for cancer spread (called a sentinel lymph node procedure).
  • People who have been diagnosed with early-stage cervical cancer and are scheduled to have a sentinel lymph node procedure.
  • People whose lymph nodes are being tested for cancer using one of two standard laboratory methods to look for signs of spread.
  • People whose lymph nodes have been found to contain cancer cells, whether a larger amount (macrometastasis) or a smaller amount (micrometastasis or isolated tumor cells).

Who may not be able to join:

  • People who have had another type of cancer (other than a common non-serious form of skin cancer) within the past 5 years, or who currently have another cancer at the same time.
  • People whose endometrial (uterine) cancer has reached an advanced or widespread stage.
  • People whose cervical cancer has reached a locally advanced or widespread stage.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fabio Martinelli, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phone: +390223903322

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Registry
ClinicalTrials.gov
Start date
2 January 2020
Est. completion
1 January 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Survival (Disease free survival [DFS], overall survival [OS]); Recurrence rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov